Consun Pharmaceutical Group Limited
CPHGF
$1.08
$0.0747.34%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.95% | 16.88% | 9.63% | 7.97% | 7.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.95% | 16.88% | 9.63% | 7.97% | 7.50% |
| Cost of Revenue | 5.31% | 6.15% | 9.66% | 8.00% | 17.98% |
| Gross Profit | 19.73% | 20.69% | 9.62% | 7.96% | 4.22% |
| SG&A Expenses | 11.28% | 12.17% | 8.07% | 6.43% | 8.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 80.41% | 80.25% | -39.23% | -37.17% | -942.95% |
| Total Operating Expenses | 13.98% | 14.89% | 8.47% | 6.82% | 6.51% |
| Operating Income | 20.21% | 21.17% | 12.08% | 10.39% | 9.72% |
| Income Before Tax | 21.03% | 22.00% | 11.20% | 9.52% | 9.50% |
| Income Tax Expenses | 47.75% | 48.93% | 7.24% | 5.62% | -4.50% |
| Earnings from Continuing Operations | 18.15% | 19.09% | 11.54% | 9.86% | 11.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -175.61% | -177.69% | -1,893.48% | -1,870.21% | -9.15% |
| Net Income | 17.40% | 18.33% | 11.19% | 9.51% | 11.28% |
| EBIT | 20.21% | 21.17% | 12.08% | 10.39% | 9.72% |
| EBITDA | 15.62% | 16.54% | 10.94% | 9.26% | 9.31% |
| EPS Basic | 10.47% | 11.58% | 9.21% | 7.76% | 10.72% |
| Normalized Basic EPS | 12.88% | 14.07% | 8.88% | 7.31% | 9.09% |
| EPS Diluted | 9.84% | 10.67% | 8.97% | 7.52% | 9.62% |
| Normalized Diluted EPS | 12.64% | 13.46% | 8.49% | 6.91% | 7.85% |
| Average Basic Shares Outstanding | 6.07% | 6.07% | 1.56% | 1.56% | 0.52% |
| Average Diluted Shares Outstanding | 6.44% | 6.44% | 1.79% | 1.79% | 1.58% |
| Dividend Per Share | 5.88% | 6.99% | 94.95% | 92.08% | -- |
| Payout Ratio | 0.67% | 0.67% | 0.88% | 0.88% | -- |